Advertisement

Picture Campus Berlin-Buch GmbH BBC BerlinBioCube Start-up Center 650x100px
Financing › Details

Trace Analytics–908 Devices: investment, 202208 acquisition $15.3m upfront cash + $2m cash milestones

 

Period Period 2022-08-09
Organisation Money taker 908 Devices Inc. (Nasdaq: MASS)
Products Product analytical instrument
  Product 2 miniaturised mass spectrometer
     

908 Devices, Inc.. (8/9/22). "Press Release: 908 Devices Acquires Trace Analytics, Enabling On-line Bioanalytics". Boston, MA.

908 Devices (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announces that it has completed the acquisition of privately-held TRACE Analytics GmbH, based in Braunschweig, Germany, a provider of on-line analysis and sampling systems for biotech applications. 908 Devices expects the acquired technology to enable its mass spec devices as on-line bioprocess monitors.

Founded in 2003, TRACE Analytics develops on-line aseptic sampling systems and novel biosensors for bioreactor monitoring and control. Their validated technology, in single-use and reusable configurations, is applied in mammalian cell culture and microbial fermentations at all levels of the bioprocess chain, from research and development to large scale production.

“The addition of TRACE Analytics enables us to take a measurable step forward in our goal to build a connected and comprehensive bioanalytics platform,” said Dr. Kevin J. Knopp, CEO and Co-founder of 908 Devices. “We are excited to have the TRACE Analytics team join us as we work together to meet the needs of our customers with on-line devices that provide actionable insights and enable Bioprocessing 4.0.”

“Our focus has been to develop robust and easy to maintain devices for bioprocess monitoring and control,” said Dr. Wolfgang Künnecke, founder of TRACE Analytics. “We feel a strong affinity with 908 Devices, and we look forward to working together to develop innovative on-line analyzers.”

The purchase consideration includes an initial cash payment of $15.3 million and up to an additional $2.0 million of contingent cash consideration upon the achievement of certain milestones over the next two years.


Webcast Information

908 Devices will discuss this acquisition on a conference call for its second quarter 2022 financial results before market open on Tuesday, August 9, 2022, at 5:30 am Pacific Time / 8:30 am Eastern Time. A webcast of the conference call can be accessed at https://ir.908devices.com/news-events/events. The webcast will be archived and available for replay for at least 90 days after the event.


About 908 Devices

908 Devices Inc. (Nasdaq: MASS) is democratizing laboratory mass spectrometry with its simple handheld and desktop devices, addressing critical-to-life applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, pharma / biopharma, forensics and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of mass spectrometry, microfluidic separations, software automation and machine learning. For more information, visit www.908devices.com.


Forward Looking Statements

This press release includes “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the expected uses and capabilities of the Company’s products. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on management’s current expectations and involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the risks outlined under “Risk Factors” and elsewhere in the Company’s filings with the Securities and Exchange Commission which are available on the SEC’s website at www.sec.gov. Additional information will be made available in the Company’s annual and quarterly reports and other filings that it makes from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.

   
Record changed: 2022-11-13

Advertisement

Picture [iito] Männer Ballett 650x80px

More documents for 908 Devices (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture Campus Berlin-Buch GmbH BBC BerlinBioCube Start-up Center 650x300px




» top